Japanese drug major Astellas Pharma (TYO: 4503) has submitted a new drug application to the Ministry of Health, Labor and Welfare in Japan for extended-release tablets of quetiapine fumarate (FK949E) for the indication of improvement of depressive symptoms associated with bipolar disorder.
Astellas has a license agreement with Anglo-Swedish peer AstraZeneca (LSE: AZN) that provides it with exclusive rights in Japan to develop and commercialize extended-release tablets of quetiapine fumarate, AstraZeneca’s now off-patent once-daily blockbuster drug Seroquel XR.
This application is based primarily on the results of a Phase-III clinical trial consisting of a placebo-controlled, double-blind, comparative study and an extension study, to confirm the efficacy and safety of extended-release tablets of quetiapine fumarate, administered orally once daily to Japanese patients diagnosed with bipolar depression. The program started following a development request from the Evaluation Committee on Unapproved or Off-label Drugs with High Medical Needs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze